{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T03:56:19Z","timestamp":1774842979066,"version":"3.50.1"},"reference-count":5,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jaad.2017.03.027","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T04:40:20Z","timestamp":1499920820000},"page":"374-377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis"],"prefix":"10.1016","volume":"77","author":[{"given":"Lavanya","family":"Mittal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2017.03.027_bib1","unstructured":"FDA Briefing Document. Paper presented at Pharmacy Compounding Advisory Committee (PCAC) Meeting; March 8-9, 2016. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/PharmacyCompoundingAdvisoryCommittee\/UCM486146.pdf. Accessed August 1, 2016."},{"issue":"3","key":"10.1016\/j.jaad.2017.03.027_bib2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/archdermatol.2011.342","article-title":"Impact of smoking in cutaneous lupus erythematosus","volume":"148","author":"Piette","year":"2012","journal-title":"Arch Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2017.03.027_bib3","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/archdermatol.2011.191","article-title":"Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis","volume":"147","author":"Chang","year":"2011","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.03.027_bib4","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/archderm.1965.01600170090017","article-title":"Aplastic anemia induced by quinacrine","volume":"92","author":"Biro","year":"1965","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.03.027_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00000441-194621220-00011","article-title":"Aplastic anemia in soldiers treated with atabrine (quinacrine)","volume":"212","author":"Custer","year":"1946","journal-title":"Am J Med Sci"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217304140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217304140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:44:31Z","timestamp":1759272271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962217304140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0190962217304140"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.03.027","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}